MediPoint: Cardiac Markers Rapid Tests and Point of Care - Global Analysis and Market Forecasts

  • ID: 4116429
  • Report
  • Region: Global
  • 110 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Abbott Point of Care
  • Alere
  • LSI Medience
  • Philips Healthcare
  • Radiometer Medical
  • Response Biomedical
  • MORE
MediPoint: Cardiac Markers Rapid Tests and Point of Care - Global Analysis and Market Forecasts

Summary

Global cardiac marker point-of-care (POC) market to remain a promising area of growth within the in vitro diagnostics (IVD) industry. In 2016, revenue from cardiac marker POC diagnostics was $311.3m across the 15 major markets (15MM: US, Canada, Mexico, France, Germany, Italy, Spain, Russia, UK, Japan, China, India, South Korea, Australia, and Brazil).

Point-of-care testing (POCT), also known as bedside testing, near-patient testing, or decentralized laboratory testing, is an emerging specialty within in vitro diagnostics (IVD). POCT is one of the most rapidly growing areas in IVD, both due to the drive to increase efficiency and therefore improve patient care, and as a result of significant technological advances.

Sales are expected to increase throughout the forecast period, reaching $397.8m across the 15MM by 2023, growing at a Compound Annual Growth Rate (CAGR) of 3.6%. Despite global sales volume increasing, market value has not increased at the same rate in recent years. This is due to rapid price erosion taking place across the major markets, driven both by regulatory pressures and increased competition.

The competitive factors in the cardiac POC space include fast TAT of test results, price, data handling techniques, and analytical performance, as well as the R&D, marketing, promotion, and brand name recognition of the company. The competitive landscape has resulted in improvements in these areas and significant price decreases over the last three years, leading to a decrease in market size in some countries.

Going forward, it is expected that adoption of cardiac marker POC to supersede the decreasing prices, resulting in overall market growth. And also the incremental improvements with existing POC technologies will continue through the forecast period, as the continued miniaturization of electronics and increased computing power that are taking place in other markets spreads to POC devices, thus escalating the clinical advantages offered by POC diagnostics compared to centralized laboratory testing.

There are relatively few major players taking up significant market share in the cardiac marker POC market, predominantly selling quantitative handheld or bench-top analyzers. In addition, many companies selling qualitative rapid test strips offer cardiac markers in their portfolio, although these tend to be sold predominantly outside the US and European markets. Abbott, Alere, and Roche are the market leaders in the cardiac marker POC market, collectively accounting for 80.4% of global sales, followed by Siemens. Beyond these market leaders, many other large or medium-sized companies are competing for the remaining market share, including LSI Medience, Radiometer Medical, Response Biomedical, and Trinity Biotech.

Companies Mentioned within the research report: Abbott Point-of-Care, Alere, LSI Medience, Philips Healthcare, Radiometer Medical, Response Biomedical, Roche Diagnostics, Siemens Healthineers and Trinity Biotech

Highlights

Key Questions Answered

- What is the current and future cardiac marker POCT market outlook in the developed and emerging markets? What trends are affecting the global market?
- What is the competitive landscape and market share of major players in the cardiac marker POCT space across different regions?
- What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
- What are the unmet needs with the cardiac marker POC tests currently on the market?
- What are the key factors influencing a physician to use cardiac marker POC tests? What is physician perception and market outlook of these devices?
- What are the challenges and barriers that have hindered widespread adoption of cardiac marker POC devices?

Scope

- Competitive assessment: Currently marketed cardiac marker POC products and evolving competitive landscape
- In-depth analysis of unmet needs and adoption trends of different cardiac marker POC devices
- Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
- Pipeline analysis: Emerging products and technologies.
- Annualized total cardiac marker POCT market revenue by segment and market outlooks by country from 2013-2022.
- Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.

Reasons to buy

The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the global market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Track device sales in the global market from 2014-2023
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Point of Care
  • Alere
  • LSI Medience
  • Philips Healthcare
  • Radiometer Medical
  • Response Biomedical
  • MORE
1 Table of Contents
2 Introduction
2.1 POC Diagnostics Overview
2.2 Catalyst
2.3 Related Reports
3 Market Opportunities
3.1 Unmet Needs
3.1.1 Improved Reliability of Tests Outside Controlled Testing Environments
3.1.2 Data Management
3.1.3 Evidence of Cost-Effectiveness or Improved Patient Outcomes
3.1.4 Markers for Myocardial Ischemia
3.2 Market Drivers
3.2.1 Fast Turnaround Time
3.2.2 Use of POC Troponin Testing in Pre-hospital Settings
3.2.3 Increased Uptake of D-Dimer Testing
3.2.4 CLIA-Waived Status for POCT
3.2.5 Rising Prevalence of Diseases
3.3 Market Barriers
3.3.1 Management of POCT
3.3.2 Disruption to Traditional Ways of Working
3.3.3 Competition with Laboratory Tests
3.3.4 Regulatory Compliance
3.3.5 Cost and Reimbursement
3.3.6 Low Uptake of Novel Biomarkers
4 Market Access
4.1 Reimbursement Trends
4.1.1 North America
4.1.2 Europe
4.1.3 APAC
4.1.4 South America
4.2 Regulatory Issues and Recalls
4.3 Mergers, Acquisitions, and Key Partnerships
5 Competitive Assessment
5.1 Company Share Analysis
5.1.1 Global
5.1.2 US
5.1.3 Europe
5.1.4 Asia-Pacific and Rest of World
5.2 Major Players
5.2.1 Abbott Point of Care
5.2.2 Alere
5.2.3 LSI Medience
5.2.4 Philips Healthcare
5.2.5 Radiometer Medical
5.2.6 Response Biomedical
5.2.7 Roche Diagnostics
5.2.8 Siemens Healthineers
5.2.9 Trinity Biotech
6 Pipeline Assessment
6.1 Overview
6.2 Troponin Tests
6.3 BNP Tests
6.4 Panel Tests
6.5 Other Biomarkers
7 Procedure Trends
7.1 Troponin Tests
7.2 B-Type Natriuretic Peptide Tests
7.3 Other Cardiac Marker Tests
8 Market Outlook
8.1 Market Segment Analysis
8.2 Global Overview
8.3 US
8.4 Canada
8.5 Mexico
8.6 France
8.7 Germany
8.8 Italy
8.9 Russia
8.10 Spain
8.11 UK
8.12 Australia
8.13 China
8.14 Japan
8.15 India
8.16 South Korea
8.17 Brazil
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Report Methodology
9.3.1 Overview
9.3.2 Coverage
9.3.3 Secondary Research
9.3.4 Forecasting Methodology
9.3.5 Primary Research - Key Opinion Leader Interviews
9.4 About the Authors
9.4.1 Analysts
9.4.2 Tyler Fletcher, Global Head of Medical Devices
9.5 About MediPoint
9.6 About
9.7 Disclaimer

List of Tables

Table 1: Advantages and Disadvantages of POCT
Table 2: Regulatory Issues and Recalls 2012-2016
Table 3: Mergers, Acquisitions, and Key Partnerships, 2015-2016
Table 4: Company Profile - Abbott Point of Care
Table 5: Abbott Point of Care Portfolio Assessment, 2016
Table 6: SWOT Analysis - Abbott Point of Care
Table 7: Company Profile - Alere
Table 8: Alere POC Portfolio Assessment, 2016
Table 9: SWOT Analysis - Alere
Table 10: Company Profile - LSI Medience
Table 11: LSI Medience POC Portfolio Assessment, 2016
Table 12: SWOT Analysis - LSI Medience
Table 13: Company Profile - Philips Healthcare
Table 14: Philips Healthcare POC Portfolio Assessment, 2016
Table 15: SWOT Analysis - Philips Healthcare
Table 16: Company Profile - Radiometer Medical
Table 17: Radiometer Medical POC Portfolio Assessment, 2016
Table 18: SWOT Analysis - Radiometer Medical
Table 19: Company Profile - Response Biomedical
Table 20: Response Biomedical POC Portfolio Assessment, 2016
Table 21: SWOT Analysis - Response Biomedical
Table 22: Company Profile - Roche Diagnostics
Table 23: Roche Diagnostics POC Portfolio Assessment, 2016
Table 24: SWOT Analysis - Roche Diagnostics
Table 25: Company Profile - Siemens Healthineers
Table 26: Siemens Healthineers POC Portfolio Assessment, 2016
Table 27: SWOT Analysis - Siemens Healthineers
Table 28: Company Profile - Trinity Biotech
Table 29: Trinity Biotech POC Portfolio Assessment, 2016
Table 30: SWOT Analysis - Trinity Biotech
Table 31: Key Troponin POCT Pipelines, 2016
Table 32: Key BNP POCT Pipelines, 2016
Table 33: Key Cardiac Panel POCT Pipelines, 2016
Table 34: Key Other Cardiac Marker POCT Pipelines, 2016
Table 35: Troponin POCT Volume (thousands) Forecast by Country, 2014-2023
Table 36: BNP POCT Volume (thousands) Forecast by Country, 2014-2023
Table 37: Other Cardiac Marker POCT Volume (thousands) Forecast by Country, 2014-2023
Table 38: Global Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 39: Global Cardiac Marker POCT Sales Forecast ($m) by Country, 2014-2023
Table 40: US Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 41: Canada Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 42: Mexico Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 43: France Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 44: Germany Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 45: Italy Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 46: Russia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 47: Spain Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 48: UK Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 49: Australia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 50: China Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 51: Japan Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 52: India Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 53: South Korea Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Table 54: Brazil Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023

List of Figures

Figure 1: Global Company Share Analysis, 2016
Figure 2: US Company Share Analysis, 2016
Figure 3: Europe Company Share Analysis, 2016
Figure 4: APAC and Rest of World Company Share Analysis, 2016
Figure 5: Troponin POCT Volume (thousands) Forecast by Region, 2014-2023
Figure 6: BNP POCT Volume (thousands) Forecast by Region, 2014-2023
Figure 7: Other Cardiac Marker POCT Volume (thousands) Forecast by Region, 2014-2023
Figure 8: Cardiac Marker POCT Sales Forecast ($m), 2014-2023
Figure 9: Global Cardiac Marker POCT Market Share ($) by Country, 2016
Figure 10: US Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 11: Canada Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 12: Mexico Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 13: France Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 14: Germany Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 15: Italy Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 16: Russia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 17: Spain Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 18: UK Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 19: Australia Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 20: China Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 21: Japan Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 22: India Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 23: South Korea Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Figure 24: Brazil Cardiac Marker POCT Sales Forecast ($m) by Market Segment, 2014-2023
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Point of Care
  • Alere
  • LSI Medience
  • Philips Healthcare
  • Radiometer Medical
  • Response Biomedical
  • Roche Diagnostics
  • Siemens Healthineers
  • Trinity Biotech
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll